Clinical Exomes Sequencing to Reporting

Online

Genomics Unlcoked

Share

Watch Webinar

Clinical Exomes Sequencing to Reporting
Clinical Exomes Sequencing to Reporting

Clinical Exome Sequencing: Harnessing the Power of MGI Sequencers for Advanced Genetic Insights

Introduction: Unraveling the Potential of Clinical Sequencing

Clinical exome sequencing (CES) is a cutting-edge technique revolutionizing our understanding of genetic diseases. In this comprehensive guide, we will explore how MGI Sequencers are reshaping research and diagnostics in genomics.

Clinical Exome Sequencing: A Comprehensive Overview

CES primarily focuses on sequencing the protein-coding regions of the genome, known as exons. Despite constituting a small portion of the genome, these regions are densely packed with disease-related genetic variants, making CES a cost-effective tool for understanding genetic disorders.

MGI Sequencers: Pioneering Precision in Genomics

MGI's range of high-throughput sequencers, including the MGI G99 and DNBSEQ-G400, are acclaimed for their reliability and superior data quality. These sequencers are integral in various genomic applications, including CES.

MGI G99 Sequencer

  • Sequencing Output: Handles up to 1 sample per flow cell.

  • Highlights: Cost-effective, ideal for genomic applications. Learn more.

MGI DNBSEQ-G400 Sequencer

  • Sequencing Output: Up to 50 samples per flow cell.

  • Highlights: High-throughput, reliable performance. Discover more.

Data Processing and Analysis Workflow

Primary Analysis

MGI sequencers process raw sequencing data into FASTQ files, offering various primary analysis options, including standalone servers and devices.

Secondary Analysis

The FASTQ files are converted into VCF files. MGI's Zitron Pro facilitates this step with its efficient hardware acceleration.

Annotation and Clinical Reporting

MGI's integrated software solutions streamline the annotation of VCF files and the generation of clinical reports.

Customizable Analysis Pipelines

MGI's tools allow integration with third-party or open-source software for secondary analysis, providing flexibility in crafting specific workflows.

Streamlining Clinical Diagnostics with Advanced Tools

Professor Charles E. Chappel: Pioneering Genetic Analysis with VarSome

Professor Chappel discusses integrating VarSome with MGI sequencers, particularly the T7 sequencer, for enhanced clinical diagnostics.

Dr. Marcela Galvez: Elevating Disease Diagnosis through Comprehensive Sequencing

Dr. Galvez highlights the critical role of sequencing technology in disease diagnosis and patient care, focusing on the complexities of CNV analysis.

Dr. Manuel Delpero: Leveraging Sequencing for Enhanced Clinical Outcomes

Dr. Delpero shares insights on using MGI sequencing tools in clinical analysis, with a focus on the practical application of the T7 sequencer in diagnostic accuracy.

Clinical Exome Sequencing: Harnessing the Power of MGI Sequencers for Advanced Genetic Insights

Introduction: Unraveling the Potential of Clinical Sequencing

Clinical exome sequencing (CES) is a cutting-edge technique revolutionizing our understanding of genetic diseases. In this comprehensive guide, we will explore how MGI Sequencers are reshaping research and diagnostics in genomics.

Clinical Exome Sequencing: A Comprehensive Overview

CES primarily focuses on sequencing the protein-coding regions of the genome, known as exons. Despite constituting a small portion of the genome, these regions are densely packed with disease-related genetic variants, making CES a cost-effective tool for understanding genetic disorders.

MGI Sequencers: Pioneering Precision in Genomics

MGI's range of high-throughput sequencers, including the MGI G99 and DNBSEQ-G400, are acclaimed for their reliability and superior data quality. These sequencers are integral in various genomic applications, including CES.

MGI G99 Sequencer

  • Sequencing Output: Handles up to 1 sample per flow cell.

  • Highlights: Cost-effective, ideal for genomic applications. Learn more.

MGI DNBSEQ-G400 Sequencer

  • Sequencing Output: Up to 50 samples per flow cell.

  • Highlights: High-throughput, reliable performance. Discover more.

Data Processing and Analysis Workflow

Primary Analysis

MGI sequencers process raw sequencing data into FASTQ files, offering various primary analysis options, including standalone servers and devices.

Secondary Analysis

The FASTQ files are converted into VCF files. MGI's Zitron Pro facilitates this step with its efficient hardware acceleration.

Annotation and Clinical Reporting

MGI's integrated software solutions streamline the annotation of VCF files and the generation of clinical reports.

Customizable Analysis Pipelines

MGI's tools allow integration with third-party or open-source software for secondary analysis, providing flexibility in crafting specific workflows.

Streamlining Clinical Diagnostics with Advanced Tools

Professor Charles E. Chappel: Pioneering Genetic Analysis with VarSome

Professor Chappel discusses integrating VarSome with MGI sequencers, particularly the T7 sequencer, for enhanced clinical diagnostics.

Dr. Marcela Galvez: Elevating Disease Diagnosis through Comprehensive Sequencing

Dr. Galvez highlights the critical role of sequencing technology in disease diagnosis and patient care, focusing on the complexities of CNV analysis.

Dr. Manuel Delpero: Leveraging Sequencing for Enhanced Clinical Outcomes

Dr. Delpero shares insights on using MGI sequencing tools in clinical analysis, with a focus on the practical application of the T7 sequencer in diagnostic accuracy.

Clinical Exome Sequencing: Harnessing the Power of MGI Sequencers for Advanced Genetic Insights

Introduction: Unraveling the Potential of Clinical Sequencing

Clinical exome sequencing (CES) is a cutting-edge technique revolutionizing our understanding of genetic diseases. In this comprehensive guide, we will explore how MGI Sequencers are reshaping research and diagnostics in genomics.

Clinical Exome Sequencing: A Comprehensive Overview

CES primarily focuses on sequencing the protein-coding regions of the genome, known as exons. Despite constituting a small portion of the genome, these regions are densely packed with disease-related genetic variants, making CES a cost-effective tool for understanding genetic disorders.

MGI Sequencers: Pioneering Precision in Genomics

MGI's range of high-throughput sequencers, including the MGI G99 and DNBSEQ-G400, are acclaimed for their reliability and superior data quality. These sequencers are integral in various genomic applications, including CES.

MGI G99 Sequencer

  • Sequencing Output: Handles up to 1 sample per flow cell.

  • Highlights: Cost-effective, ideal for genomic applications. Learn more.

MGI DNBSEQ-G400 Sequencer

  • Sequencing Output: Up to 50 samples per flow cell.

  • Highlights: High-throughput, reliable performance. Discover more.

Data Processing and Analysis Workflow

Primary Analysis

MGI sequencers process raw sequencing data into FASTQ files, offering various primary analysis options, including standalone servers and devices.

Secondary Analysis

The FASTQ files are converted into VCF files. MGI's Zitron Pro facilitates this step with its efficient hardware acceleration.

Annotation and Clinical Reporting

MGI's integrated software solutions streamline the annotation of VCF files and the generation of clinical reports.

Customizable Analysis Pipelines

MGI's tools allow integration with third-party or open-source software for secondary analysis, providing flexibility in crafting specific workflows.

Streamlining Clinical Diagnostics with Advanced Tools

Professor Charles E. Chappel: Pioneering Genetic Analysis with VarSome

Professor Chappel discusses integrating VarSome with MGI sequencers, particularly the T7 sequencer, for enhanced clinical diagnostics.

Dr. Marcela Galvez: Elevating Disease Diagnosis through Comprehensive Sequencing

Dr. Galvez highlights the critical role of sequencing technology in disease diagnosis and patient care, focusing on the complexities of CNV analysis.

Dr. Manuel Delpero: Leveraging Sequencing for Enhanced Clinical Outcomes

Dr. Delpero shares insights on using MGI sequencing tools in clinical analysis, with a focus on the practical application of the T7 sequencer in diagnostic accuracy.

Clinical Exome Sequencing: Harnessing the Power of MGI Sequencers for Advanced Genetic Insights

Introduction: Unraveling the Potential of Clinical Sequencing

Clinical exome sequencing (CES) is a cutting-edge technique revolutionizing our understanding of genetic diseases. In this comprehensive guide, we will explore how MGI Sequencers are reshaping research and diagnostics in genomics.

Clinical Exome Sequencing: A Comprehensive Overview

CES primarily focuses on sequencing the protein-coding regions of the genome, known as exons. Despite constituting a small portion of the genome, these regions are densely packed with disease-related genetic variants, making CES a cost-effective tool for understanding genetic disorders.

MGI Sequencers: Pioneering Precision in Genomics

MGI's range of high-throughput sequencers, including the MGI G99 and DNBSEQ-G400, are acclaimed for their reliability and superior data quality. These sequencers are integral in various genomic applications, including CES.

MGI G99 Sequencer

  • Sequencing Output: Handles up to 1 sample per flow cell.

  • Highlights: Cost-effective, ideal for genomic applications. Learn more.

MGI DNBSEQ-G400 Sequencer

  • Sequencing Output: Up to 50 samples per flow cell.

  • Highlights: High-throughput, reliable performance. Discover more.

Data Processing and Analysis Workflow

Primary Analysis

MGI sequencers process raw sequencing data into FASTQ files, offering various primary analysis options, including standalone servers and devices.

Secondary Analysis

The FASTQ files are converted into VCF files. MGI's Zitron Pro facilitates this step with its efficient hardware acceleration.

Annotation and Clinical Reporting

MGI's integrated software solutions streamline the annotation of VCF files and the generation of clinical reports.

Customizable Analysis Pipelines

MGI's tools allow integration with third-party or open-source software for secondary analysis, providing flexibility in crafting specific workflows.

Streamlining Clinical Diagnostics with Advanced Tools

Professor Charles E. Chappel: Pioneering Genetic Analysis with VarSome

Professor Chappel discusses integrating VarSome with MGI sequencers, particularly the T7 sequencer, for enhanced clinical diagnostics.

Dr. Marcela Galvez: Elevating Disease Diagnosis through Comprehensive Sequencing

Dr. Galvez highlights the critical role of sequencing technology in disease diagnosis and patient care, focusing on the complexities of CNV analysis.

Dr. Manuel Delpero: Leveraging Sequencing for Enhanced Clinical Outcomes

Dr. Delpero shares insights on using MGI sequencing tools in clinical analysis, with a focus on the practical application of the T7 sequencer in diagnostic accuracy.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

Challenges and Considerations in Clinical Exome Sequencing

Clinical exome sequencing, while offering vast potential, presents unique challenges:

Secondary Findings

Addressing secondary findings requires informed consent, adhering to guidelines set by the American College of Medical Genetics.

CNV Calling and Analysis

The detection and analysis of CNVs demand rigorous validation to ensure accuracy.

Variants of Uncertain Significance

Interpreting VUS is complex, necessitating ongoing discussions about their clinical relevance.

Periodic Reclassification

As genomic knowledge evolves, reclassification of variants is crucial to provide patients with updated and accurate genetic information. Establishing a system for regular re-evaluation of variants ensures that patients benefit from the latest genomic insights.

The Future of Clinical Exome Sequencing

The field of clinical exome sequencing is rapidly advancing, driven by continuous technological innovations and a deeper understanding of genetic diseases. Future trends and developments are likely to include:

Integration of AI and Machine Learning

Artificial intelligence and machine learning are set to play a significant role in interpreting sequencing data. These technologies can streamline the analysis process, enhance the accuracy of variant interpretation, and identify patterns that may be missed by traditional methods.

Expanded Use in Personalized Medicine

Clinical exome sequencing is poised to become a cornerstone in personalized medicine. By providing detailed genetic insights, it enables tailored treatment plans based on an individual's genetic makeup, improving outcomes and reducing the risk of adverse reactions.

Ethical and Privacy Considerations

As sequencing becomes more widespread, ethical and privacy concerns will come to the forefront. Balancing the benefits of genetic insights with the right to privacy and informed consent will be a key challenge for the field.

Collaborative Research and Data Sharing

Collaborations across research institutions and sharing of genomic data can accelerate the discovery of new genetic markers and disease associations. This collaborative approach can lead to breakthroughs in understanding complex genetic disorders.

Conclusion: Embracing the Era of Genomic Medicine

Clinical exome sequencing, with the aid of advanced MGI sequencers and the expertise of professionals like Prof. Chappel, Dr. Galvez, and Dr. Delpero, is transforming the landscape of genetic research and diagnostics. As we embrace this era of genomic medicine, the potential for groundbreaking discoveries and enhanced patient care is immense. The future of clinical exome sequencing is not just about technological advances but also about the ethical, collaborative, and patient-centric approach that will define its role in healthcare.

By keeping pace with these advancements and addressing the associated challenges, we can unlock the full potential of clinical exome sequencing, leading to a new frontier in personalized medicine and improved health outcomes.


Challenges and Considerations in Clinical Exome Sequencing

Clinical exome sequencing, while offering vast potential, presents unique challenges:

Secondary Findings

Addressing secondary findings requires informed consent, adhering to guidelines set by the American College of Medical Genetics.

CNV Calling and Analysis

The detection and analysis of CNVs demand rigorous validation to ensure accuracy.

Variants of Uncertain Significance

Interpreting VUS is complex, necessitating ongoing discussions about their clinical relevance.

Periodic Reclassification

As genomic knowledge evolves, reclassification of variants is crucial to provide patients with updated and accurate genetic information. Establishing a system for regular re-evaluation of variants ensures that patients benefit from the latest genomic insights.

The Future of Clinical Exome Sequencing

The field of clinical exome sequencing is rapidly advancing, driven by continuous technological innovations and a deeper understanding of genetic diseases. Future trends and developments are likely to include:

Integration of AI and Machine Learning

Artificial intelligence and machine learning are set to play a significant role in interpreting sequencing data. These technologies can streamline the analysis process, enhance the accuracy of variant interpretation, and identify patterns that may be missed by traditional methods.

Expanded Use in Personalized Medicine

Clinical exome sequencing is poised to become a cornerstone in personalized medicine. By providing detailed genetic insights, it enables tailored treatment plans based on an individual's genetic makeup, improving outcomes and reducing the risk of adverse reactions.

Ethical and Privacy Considerations

As sequencing becomes more widespread, ethical and privacy concerns will come to the forefront. Balancing the benefits of genetic insights with the right to privacy and informed consent will be a key challenge for the field.

Collaborative Research and Data Sharing

Collaborations across research institutions and sharing of genomic data can accelerate the discovery of new genetic markers and disease associations. This collaborative approach can lead to breakthroughs in understanding complex genetic disorders.

Conclusion: Embracing the Era of Genomic Medicine

Clinical exome sequencing, with the aid of advanced MGI sequencers and the expertise of professionals like Prof. Chappel, Dr. Galvez, and Dr. Delpero, is transforming the landscape of genetic research and diagnostics. As we embrace this era of genomic medicine, the potential for groundbreaking discoveries and enhanced patient care is immense. The future of clinical exome sequencing is not just about technological advances but also about the ethical, collaborative, and patient-centric approach that will define its role in healthcare.

By keeping pace with these advancements and addressing the associated challenges, we can unlock the full potential of clinical exome sequencing, leading to a new frontier in personalized medicine and improved health outcomes.


Challenges and Considerations in Clinical Exome Sequencing

Clinical exome sequencing, while offering vast potential, presents unique challenges:

Secondary Findings

Addressing secondary findings requires informed consent, adhering to guidelines set by the American College of Medical Genetics.

CNV Calling and Analysis

The detection and analysis of CNVs demand rigorous validation to ensure accuracy.

Variants of Uncertain Significance

Interpreting VUS is complex, necessitating ongoing discussions about their clinical relevance.

Periodic Reclassification

As genomic knowledge evolves, reclassification of variants is crucial to provide patients with updated and accurate genetic information. Establishing a system for regular re-evaluation of variants ensures that patients benefit from the latest genomic insights.

The Future of Clinical Exome Sequencing

The field of clinical exome sequencing is rapidly advancing, driven by continuous technological innovations and a deeper understanding of genetic diseases. Future trends and developments are likely to include:

Integration of AI and Machine Learning

Artificial intelligence and machine learning are set to play a significant role in interpreting sequencing data. These technologies can streamline the analysis process, enhance the accuracy of variant interpretation, and identify patterns that may be missed by traditional methods.

Expanded Use in Personalized Medicine

Clinical exome sequencing is poised to become a cornerstone in personalized medicine. By providing detailed genetic insights, it enables tailored treatment plans based on an individual's genetic makeup, improving outcomes and reducing the risk of adverse reactions.

Ethical and Privacy Considerations

As sequencing becomes more widespread, ethical and privacy concerns will come to the forefront. Balancing the benefits of genetic insights with the right to privacy and informed consent will be a key challenge for the field.

Collaborative Research and Data Sharing

Collaborations across research institutions and sharing of genomic data can accelerate the discovery of new genetic markers and disease associations. This collaborative approach can lead to breakthroughs in understanding complex genetic disorders.

Conclusion: Embracing the Era of Genomic Medicine

Clinical exome sequencing, with the aid of advanced MGI sequencers and the expertise of professionals like Prof. Chappel, Dr. Galvez, and Dr. Delpero, is transforming the landscape of genetic research and diagnostics. As we embrace this era of genomic medicine, the potential for groundbreaking discoveries and enhanced patient care is immense. The future of clinical exome sequencing is not just about technological advances but also about the ethical, collaborative, and patient-centric approach that will define its role in healthcare.

By keeping pace with these advancements and addressing the associated challenges, we can unlock the full potential of clinical exome sequencing, leading to a new frontier in personalized medicine and improved health outcomes.


Challenges and Considerations in Clinical Exome Sequencing

Clinical exome sequencing, while offering vast potential, presents unique challenges:

Secondary Findings

Addressing secondary findings requires informed consent, adhering to guidelines set by the American College of Medical Genetics.

CNV Calling and Analysis

The detection and analysis of CNVs demand rigorous validation to ensure accuracy.

Variants of Uncertain Significance

Interpreting VUS is complex, necessitating ongoing discussions about their clinical relevance.

Periodic Reclassification

As genomic knowledge evolves, reclassification of variants is crucial to provide patients with updated and accurate genetic information. Establishing a system for regular re-evaluation of variants ensures that patients benefit from the latest genomic insights.

The Future of Clinical Exome Sequencing

The field of clinical exome sequencing is rapidly advancing, driven by continuous technological innovations and a deeper understanding of genetic diseases. Future trends and developments are likely to include:

Integration of AI and Machine Learning

Artificial intelligence and machine learning are set to play a significant role in interpreting sequencing data. These technologies can streamline the analysis process, enhance the accuracy of variant interpretation, and identify patterns that may be missed by traditional methods.

Expanded Use in Personalized Medicine

Clinical exome sequencing is poised to become a cornerstone in personalized medicine. By providing detailed genetic insights, it enables tailored treatment plans based on an individual's genetic makeup, improving outcomes and reducing the risk of adverse reactions.

Ethical and Privacy Considerations

As sequencing becomes more widespread, ethical and privacy concerns will come to the forefront. Balancing the benefits of genetic insights with the right to privacy and informed consent will be a key challenge for the field.

Collaborative Research and Data Sharing

Collaborations across research institutions and sharing of genomic data can accelerate the discovery of new genetic markers and disease associations. This collaborative approach can lead to breakthroughs in understanding complex genetic disorders.

Conclusion: Embracing the Era of Genomic Medicine

Clinical exome sequencing, with the aid of advanced MGI sequencers and the expertise of professionals like Prof. Chappel, Dr. Galvez, and Dr. Delpero, is transforming the landscape of genetic research and diagnostics. As we embrace this era of genomic medicine, the potential for groundbreaking discoveries and enhanced patient care is immense. The future of clinical exome sequencing is not just about technological advances but also about the ethical, collaborative, and patient-centric approach that will define its role in healthcare.

By keeping pace with these advancements and addressing the associated challenges, we can unlock the full potential of clinical exome sequencing, leading to a new frontier in personalized medicine and improved health outcomes.


Clinical Exome Sequencing

Genomics Analysis

ACMG Classification

Family Trio Analysis

Share this article :

Share

More Events

Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024

Mar 18, 2024

Join MGI at Spatial Biology UK 2024

Discover Genomic Innovations with MGI at Spatial Biology UK 2024! Join us on March 18th-19th at booth 15 at Novotel London West. Don't miss out!

Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference

Jan 27, 2024

Join us at EACR-AACR-IACR Basic and Translational Research Conference

Join us at booth 5 during the EACR-AACR-IACR Basic and Translational Research Conference with the MGI Team in Dublin, Ireland from February 27-29.

Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January

Jan 24, 2024

Join us at The Festival of Genomics & Biodata in January

Join us at booth 98 with MGI Tech during The Festival of Genomics & Biodata on January 24th-25th, 2024, at ExCeL in London.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.